Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy

Clinical Immunology

Volumn 141, Issue 1, 2011, Pages 90-102

  Jolles, S ^a   Bernatowska, E ^b   de Gracia, J ^c   Borte, M ^d   Cristea, V ^e   Peter, H H ^f   Belohradsky, B H ^g   Wahn, V ^h   Neufang Huber J ⁱ   Zenker, O ^j   Grimbacher, B ^k  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b Child Health Institute   (Poland)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^f UNIVERSITY OF FREIBURG   (Germany)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ ZLB Behring AG   (Switzerland)

^j CSL BEHRING GMBH   (Germany)

^k ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

more..

Author keywords

Hizentra; IgG levels; IgPro20; Local reactions; Primary immunodeficiency; Subcutaneous IgG

Indexed keywords

ANTIBIOTIC AGENT; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; AGED; APPENDICITIS; AREA UNDER THE CURVE; ARTICLE; BRONCHIOLITIS; CHILD; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INFECTION; INJECTION SITE PRURITUS; ISCHIALGIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; RESPIRATORY TRACT INFECTION; SCHOOL; SCHOOL CHILD; SIDE EFFECT; SUBSTITUTION THERAPY; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADOLESCENT; ADULT; AGAMMAGLOBULINEMIA; CHILD; CHILD, PRESCHOOL; COMMON VARIABLE IMMUNODEFICIENCY; FEMALE; GENETIC DISEASES, X-LINKED; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFUSIONS, INTRAVENOUS; INFUSIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052617229     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.06.002     Document Type: Article

References (43)

1. Buckley R.H. Primary immunodeficiency diseases due to defects in lymphocytes. N. Engl. J. Med. 2000, 343:1313-1324.
2. Chapel H., Geha R., Rosen F. Primary immunodeficiency diseases: an update. Clin. Exp. Immunol. 2003, 132:9-15.
3. Cunningham-Rundles C., Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin. Immunol. 1999, 92:34-48.
4. Lougaris V., Ferrari S., Plebani A. Ig beta deficiency in humans. Curr. Opin. Allergy Clin. Immunol. 2008, 8:515-519.
5. Ochs H.D., Smith C.I.E., Puck J.M. Primary Immunodeficiency Diseases: A Molecular and Genetic Approach 2007, Oxford University Press Inc., USA, New York.
6. Park M.A., Li J.T., Hagan J.B., Maddox D.E., Abraham R.S. Common variable immunodeficiency: a new look at an old disease. Lancet 2008, 372:489-502.
7. Notarangelo L.D., Fischer A., Geha R.S., Casanova J.L., Chapel H., Conley M.E., Cunningham-Rundles C., Etzioni A., Hammartrom L., Nonoyama S., Ochs H.D., Puck J., Roifman C., Seger R., Wedgwood J. Primary immunodeficiencies: 2009 update. J. Allergy Clin. Immunol. 2009, 124:1161-1178.
8. Busse P.J., Razvi S., Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J. Allergy Clin. Immunol. 2002, 109:1001-1004.
9. Bussel J.B., Eldor A., Kelton J.G., Varon D., Brenner B., Gillis S., Angiolillo A., Kulkarni R., Abshire T.C., Kelleher J. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb. Haemost. 2004, 91:771-778.
10. Church J.A., Borte M., Taki H., Nelson R.P., Sleasman J.W., Knutsen A.P., Le G.E., Debre M., Kiessling P. Efficacy and safety of Privigen in children and adolescents with primary immunodeficiency. Pediatr. Asthma Allergy Immunol. 2009, 22:53-62.
11. de Gracia J., Vendrell M., Alvarez A., Pallisa E., Rodrigo M.J., de la Rosa D., Mata F., Andreu J., Morell F. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int. Immunopharmacol. 2004, 4:745-753.
12. Eijkhout H.W., van der Meer J.W., Kallenberg C.G., Weening R.S., van Dissel J.T., Sanders L.A., Strengers P.F., Nienhuis H., Schellekens P.T. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann. Intern. Med. 2001, 135:165-174.
13. Quartier P., Debre M., De Blic J., de Sauverzac R., Sayegh N., Jabado N., Haddad E., Blanche S., Casanova J.L., Smith C.I., Le D.F., de Saint B.G., Fischer A. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J. Pediatr. 1999, 134:589-596.
14. ®, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J. Clin. Immunol. 2009, 29:137-144.
15. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol. Allergy Clin. North Am. 2008, 28:413-437.
16. Berger M. Subcutaneous administration of IgG. Immunol. Allergy Clin. North Am. 2008, 28:779-802. viii.
17. Gardulf A., Hammarstrom L., Smith C.I. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991, 338:162-166.
18. Gardulf A., Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr. Opin. Allergy Clin. Immunol. 2006, 6:434-442.
19. Gardulf A., Nicolay U., Asensio O., Bernatowska E., Bock A., Carvalho B.C., Granert C., Haag S., Hernandez D., Kiessling P., Kus J., Pons J., Niehues T., Schmidt S., Schulze I., Borte M. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies-a prospective, multi-national study. J. Clin. Immunol. 2006, 26:177-185.
20. Ochs H.D., Gupta S., Kiessling P., Nicolay U., Berger M. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J. Clin. Immunol. 2006, 26:265-273.
21. Maeder W., Lieby P., Sebald A., Spycher M., Pedrussio R., Bolli R. Local tolerance and stability up to 24months of a new 20% proline-stabilized polyclonal immunoglobulin for subcutaneous administration. Biologicals 2011, 39:43-49.
22. Stucki M., Boschetti N., Schaefer W., Hostettler T., Kaesermann F., Nowak T., Groener A., Kempf C. Investigations of prion and virus safety of a new liquid IVIG product. Biologicals 2008, 36:239-247.
23. European Agency for the Evaluation of Medicinal Products (EMEA) Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use 2002, EMEA/CPMP/BPWG/282/00.
24. Hagan J.B., Fasano M.B., Spector S., Wasserman R.L., Melamed I., Rojavin M.A., Zenker O., Orange J.S. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J. Clin. Immunol. 2010, 30:734-745.
25. Conley M.E., Notarangelo L.D., Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin. Immunol. 1999, 93:190-197.
26. Center for Biologics Evaluation and Research US FDA Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency. Guidance for Industry 2008.
27. Wasserman R.L., Melamed I., Nelson R.P., Knutsen A.P., Fasano M.B., Stein M.R., Rojavin M.A., Church J.A. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin. Pharmacokinetics 2011, 50:405-414.
28. Atkinson M.J., Sinha A., Hass S.L., Colman S.S., Kumar R.N., Brod M., Rowland C.R. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual. Life Outcomes 2004, 2:12-24.
29. European Agency for the Evaluation of Medicinal Products (EMEA) Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use 2002, EMEA/CPMP/BPWG/283/00.
30. Center for Biologics Evaluation and Research US FDA Blood Products Advisory Committee Meeting August 16, 2007.
31. Peltola H., Kayhty H., Virtanen M., Makela P.H. Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N. Engl. J. Med. 1984, 310:1561-1566.
32. Ercan T.E., Soycan L.Y., Apak H., Celkan T., Ozkan A., Akdenizli E., Kasapcopur O., Yildiz I. Antibody titers and immune response to diphtheria-tetanus-pertussis and measles-mumps-rubella vaccination in children treated for acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 2005, 27:273-277.
33. Druml W., Heinzel G., Kleinberger G. Amino acid kinetics in patients with sepsis. Am. J. Clin. Nutr. 2001, 73:908-913.
34. Chapel H.M., Spickett G.P., Ericson D., Engl W., Eibl M.M., Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J. Clin. Immunol. 2000, 20:94-100.
35. Fasth A., Nystrom J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr. 2007, 96:1474-1478.
36. Lucas M., Lee M., Lortan J., Lopez-Granados E., Misbah S., Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22years. J. Allergy Clin. Immunol. 2010, 125:1354-1360.
37. Gardulf A., Andersen V., Bjorkander J., Ericson D., Froland S.S., Gustafson R., Hammarstrom L., Jacobsen M.B., Jonsson E., Moller G., Nystrom T., Soeberg B., Smith C.I.E. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995, 345:365-369.
38. Sneller M.C., Strober W., Eisenstein E., Jaffe J.S., Cunningham Rundles C. New insights into common variable immunodeficiency. Ann. Intern. Med. 1993, 118:720-730.
39. Ballow M., Notarangelo L., Grimbacher B., Cunningham-Rundles C., Stein M., Helbert M., Gathmann B., Kindle G., Knight A.K., Ochs H.D., Sullivan K., Franco J.L. Immunodeficiencies. Clin. Exp. Immunol. 2009, 158(Suppl. 1):14-22.
40. Orange J.S., Grossman W.J., Navickis R.J., Wilkes M.M. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin. Immunol. 2010, 137:21-30.
41. Roifman C.M., Schroeder H., Berger M., Sorensen R., Ballow M., Buckley R.H., Gewurz A., Korenblat P., Sussman G., Lemm G. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int. Immunopharmacol. 2003, 3:1325-1333.
42. Berger M., Pinciaro P.J. Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases. J. Clin. Immunol. 2004, 24:389-396.
43. Ochs H.D., Pinciaro P.J. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J. Clin. Immunol. 2004, 24:309-314.